AstraZeneca has for the first time officially acknowledged in court documents that its Covid-19 vaccine, sold as Covishield in India and Vaxzevria elsewhere, could cause a rare side-effect called Thrombosis Thrombocytopenia Syndrome (TTS). This comes after a UK-based man, Jamie Scott, was left with a permanent brain injury due to blood clotting and low platelet count after receiving the vaccine. AstraZeneca is now facing 51 legal cases in the UK with victims seeking up to 100 million British pounds in compensation. The company, however, has contested these claims but has accepted that the vaccine can cause TTS in very rare cases.
AstraZeneca Vaccine Linked to Rare Blood-Clotting Side Effect
Background:
AstraZeneca, a British-Swedish pharmaceutical company, developed a COVID-19 vaccine called Vaxzevria (also known as Covishield in India). The vaccine utilized an adenovirus vector technology to carry genetic material of the virus into cells, triggering an immune response.
Court Acknowledgement of Blood-Clotting Side Effect:
Recently, AstraZeneca acknowledged in court documents that its COVID-19 vaccine could cause a rare side effect called Thrombosis Thrombocytopenia Syndrome (TTS). TTS is characterized by the formation of blood clots in the brain and a low platelet count.
Legal Cases and Compensation Claims:
Following reports of TTS cases linked to the AstraZeneca vaccine, a UK-based man, Jamie Scott, filed a lawsuit alleging he suffered a permanent brain injury after receiving the shot. The case has sparked 51 legal claims in the UK, with victims seeking up to 100 million British pounds in compensation.
AstraZeneca's Response:
AstraZeneca has contested the claims of the victims, maintaining that the vaccine is safe and effective. However, the company has accepted that TTS can occur in very rare cases.
Top 5 FAQs and Answers
1. What is Thrombosis Thrombocytopenia Syndrome (TTS)?
TTS is a rare blood-clotting disorder that can occur after vaccination with the AstraZeneca COVID-19 vaccine. It involves the formation of blood clots in the brain and a low platelet count.
2. How common is TTS?
TTS is a very rare side effect of the AstraZeneca vaccine, estimated to affect around 1 in 100,000 recipients.
3. What are the symptoms of TTS?
Symptoms of TTS include severe headache, blurred vision, slurred speech, weakness or numbness on one side of the body, difficulty breathing, and chest pain.
4. What is the treatment for TTS?
Treatment for TTS typically involves administering intravenous immunoglobulin and anticoagulants to prevent further blood clots.
5. Is the AstraZeneca vaccine safe for use?
The AstraZeneca vaccine is safe and effective in preventing severe COVID-19 illness and death. However, individuals with a history of blood-clotting disorders or those at high risk of TTS should consult with their healthcare provider before receiving the AstraZeneca vaccine.
The Indian government has appointed V Narayanan as the new chairman of the Indian Space Research Organisation and Secretary, Department of Space. An IIT alumnus and cryogenic engine developer, Narayanan is expected to take charge from the current head of the organisation, S Somanath, on January 14. With years of experience and expertise in rocket and spacecraft propulsion, Narayanan aims to take ISRO to greater heights and continue India's development in space technology.
The state of Gujarat has taken precautionary measures to handle cases of HMPV, a respiratory virus, after one case was detected in a two-month-old boy two weeks ago. Three civil hospitals in Gandhinagar, Ahmedabad, and Rajkot have created isolation wards with a total of 45 beds to handle any potential health emergency. The health department has also issued an advisory to the public to prevent the spread of the virus. However, according to data from the Indian Council of Medical Research and the Integrated Disease Surveillance Programme, there has been no alarming surge in respiratory illnesses in the country.
The recent detection of the Human Metapneumovirus (HMPV) in India has sparked fears of a potential new outbreak similar to the COVID-19 pandemic. However, medical authorities assure the public that HMPV has been circulating globally for years and is not a new virus. While three cases have been reported in India, there is no need to press the panic button as there has been no unusual surge in respiratory illness cases in the country. Karnataka's Health Minister Dinesh Gundu Rao stresses that this is not the first case of HMPV in India and it is not something new.
As China experiences an outbreak of Human Metapneumovirus, also known as HMPV, health officials in Telangana, India have issued a list of precautions for the public, despite no reported cases in the state. The respiratory virus, which primarily affects children, immunocompromised individuals, and the elderly, can lead to a wide range of symptoms, including mild cold-like illness and more serious respiratory conditions. However, the Indian health agency has assured that there is no cause for alarm and that the country does not need to worry at this time.
Renowned nuclear scientist and key figure in India's nuclear program, Dr. R Chidambaram, passed away at the age of 88. He was known for his contributions to nuclear research and played a significant role in India's nuclear tests and the country's civil nuclear agreement with the United States. His passing marks a significant loss for the scientific community and the country's progress in the field of nuclear technology.
The recent spread of a new virus, human metapneumovirus (HMPV), in China has sparked global concerns, with reports of increasing cases among children under 14. However, Indian health experts and the Union Ministry of Health and Family Welfare have dismissed the possibility of a widespread disruption. This is due to previous knowledge about HMPV and its similarity to respiratory syncytial virus (RSV), a common respiratory pathogen. While HMPV may be a trigger for asthma in infants, it is not as deadly as Covid-19 and there is no reason for alarm yet.
China's disease control authorities have launched pilot systems to monitor and report cases of Human Metapneumovirus (HMPV), which has been linked to a recent flu outbreak. As the country continues to battle this respiratory virus, the World Health Organization calls for transparency and cooperation in researching the origins of COVID-19 to better prevent and prepare for future epidemics. Experts warn that people with weak respiratory health and weakened immune systems, as well as young children and the elderly, are most at risk for HMPV and urge preventive measures such as frequent hand washing and wearing masks.
Amidst growing concerns over the coronavirus outbreak, China confirms an increase in cases of human metapneumovirus (HMPV) among children under 14 years old, especially in northern provinces. HMPV is a respiratory illness similar to the common cold, with symptoms including coughing, runny nose, and sore throat. Health officials are urging the public not to blindly use antiviral drugs to fight HMPV, as there is currently no vaccine against the virus. Antibiotics may be prescribed in extreme cases where HMPV has caused pneumonia and a secondary bacterial infection.
The University Grants Commission (UGC) has announced draft guidelines for introducing skill-based courses and micro-credentials in higher education institutions, aligning with the objectives of the National Education Policy 2020. These courses, including emerging fields such as data analytics and AI, aim to enhance students' employability and support economic growth through a qualified workforce. Feedback on the guidelines will be accepted for the next 30 days, giving students and educators a chance to provide their input.
Indian Space Research Organisation (ISRO) has successfully placed two satellites, weighing 220kg, into a circular orbit of 475 km for a crucial space docking technology demonstration. This mission also included the launch of POEM-4 with 24 payloads from startups, industries, and academia. Scientist S Somanath stated that the docking process is expected to take place on January 7, after operations at ISTRAC Bengaluru from December 31. This mission is a major step towards future space missions for India.